{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'listed in Section 10.8.1 (ie, results in a low failure rate', 'when used consistently and correctly) during the dosing', 'period and for a period of at least 3 months after the end', 'of treatment.', 'A pregnancy test will be performed on each', 'premenopausal female patient of childbearing potential', 'prior to the first dose of study drug, on Day 1 of Cycles >2', 'while on treatment, and again at treatment discontinuation', 'during the End-of-Treatment visit. A negative pregnancy', 'test must be documented prior to administration of study', 'drug.', 'If a patient is confirmed pregnant during the study, study', 'drug administration must be discontinued immediately.', \"The Investigator must immediately notify the Sponsor's\", 'Medical Monitor of the event and record the pregnancy on', 'the Pregnancy Form (provided by Karyopharm). The', 'initial information regarding a pregnancy must be', \"forwarded to Karyopharm's Pharmacovigilance by email\", 'or fax within 24 hours of first knowledge of its', 'occurrence.', 'The pregnancy should be followed up to determine the', 'outcome, including spontaneous or voluntary termination,', 'details of the birth, and any birth defects, congenital', 'abnormalities, or maternal and/or newborn complications.', 'Pregnancies must be reported to Karyopharm, regardless', 'of whether the patient withdraws from the study or the', 'study is completed, for 3 months after the patient receives', 'his/ her last dose of study treatment. Patients should be', 'instructed to inform the Investigator regarding any', 'pregnancies.', 'All pregnancies occurring within 3 months after the', \"patient's last dose of study drug must be reported to\", 'Karyopharm, regardless of whether the patient received', 'selinexor or other study drugs, withdraws from the study,', 'Confidential', 'Page 129', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'or the study is completed. Patients should be instructed to', 'inform the Investigator regarding any pregnancies.', 'Any SAE that occurs during pregnancy must be recorded', 'on the SAE report form (eg, maternal serious', 'complications, therapeutic abortion, ectopic pregnancy,', 'stillbirth, neonatal death, congenital anomaly, or birth', 'defect) and reported within 24 hours in accordance with', 'the procedure for reporting SAEs (described in Section', '12.2.3).', 'A pregnancy in a female partner of a male patient must be', 'reported to Karyopharm within 24 hours of learning of its', 'occurrence. Pregnancies in female partners should only be', 'followed if the male patient is being treated with a', 'selinexor-containing regimen. Consent to report', 'information regarding these pregnancy outcomes should', 'be obtained from the female partner.', 'It is not known whether selinexor passes into the breast', 'milk. Mothers should not breastfeed while being treated', 'with selinexor-containing regimen.', 'Section 10.2.3.2: Selinexor', 'Clarified the wording for how selinexor should be', 'To align with the guidance in the current', 'administered and removed the need to take selinexor with', \"Selinexor Investigator's Brochure (IB)\", 'food.', 'Selinexor tablets should be taken with food, or within', '30 minutes after the patient has eaten, together orally with', 'at least 120 mL (4 ounces) of fluids-water at', 'approximately the same time each day. It can be taken', 'with or without food. Selinexor tablets should be', 'swallowed whole (not crushed) to prevent an increased', 'risk of dermatologic toxicity if the powder comes in', 'contact with skin.', 'Confidential', 'Page 130', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'Section 10.5.1: Missed Doses of', 'Revised the guidance for doses of study treatment that', '1) To provide 72 hours between 2 consecutive', 'Study Treatments (Selinexor,', 'must be missed due to protocol- or study-related reasons', 'doses of bortezomib in a week for patients in', 'Bortezomib, and Dexamethasone)', 'to:', 'the Vd Arm as required in the VelcadeR', '1) Provide 72 hours between 2 consecutive doses of', 'Prescribing Information', 'bortezomib', '2) To clarify that the next dose for study', '2) Remove the requirement for 36 hours between doses', 'treatments missed due to protocol- or study-', 'Section 10.5.1 Missed Doses of Study Treatments', 'related reasons should be taken per schedule', '(Selinexor, Bortezomib, and Dexamethasone)', 'and to remove the requirement for 36 hours', 'between doses', 'Missed doses of all study treatments should be managed', 'as follows:', 'For doses missed for protocol- or study-related reasons', '(eg, due to recommendation of the Investigator, such as', 'due to an AE):', 'If a dose was missed, the schedule of that week', 'should be altered to accommodate 2 doses in that', 'week with at least 36 hours between 2 consecutive', 'doses.', 'If a dose must be skipped (e.g., due to', 'recommendation of the Investigator), the next dose', 'will be taken as per schedule. Doses should not be', 'administered less than 36 hours apart, and all', 'missed and delayed doses should be documented.', 'Missed dose of bortezomib for patients in the Vd', 'Arm Only: If a bortezomib dose was missed, the', 'schedule of that week should be altered to', 'accommodate 2 doses in that week with at least 72', 'hours between 2 consecutive doses of bortezomib.', 'Missed dose of any study treatment for all', 'patients: If a dose of any study treatment must be', 'missed, the next dose will be taken as per schedule.', 'All missed and delayed doses should be', 'documented.', 'Confidential', 'Page 131', 'Version 4.0']\n\n###\n\n", "completion": "END"}